Clipping of news on Brazilian Culture, Law and Citizenship
09/12/2014
This article was translated by an automatic translation system, and was therefore not reviewed by people.
transparent image
The National Health Surveillance Agency (ANVISA) approved on Monday a new drug to treat people with rheumatoid arthritis who have not responded to conventional treatment.
Tofacitinibe citrate, which is marketed under the name of Pfizer Xeljanz the pharmaceutical is approved in about 30 countries. In the United States, for example, was released in November 2012.
Rheumatoid arthritis is an autoimmune disease in which the patient's immune system attacks healthy tissue leading to inflammation in the joints. About 1% of the population has the problem. Initial treatment of the disease is done with the drug methotrexate, but between 30% and 50% of patients do not respond to the drug. In such cases, we indicate the exchange of drug or combination with other medication. If the approach is not positive, doctors prescribe biologic drugs that are injected.
The Xeljanz work as another option for patients who failed to respond to methotrexate, preventing or postponing thus the injectable treatment. The new drug has a different mechanism of action of currently available drugs. The substance acting inside cells, by inhibiting the action of the kinase, a protein that contributes to the inflammation process.
Source: View - Online
Our news are taken in full of our partner sites. For this reason, we can not change their content even in cases of typos. transparent image
This article was translated by an automatic translation system, and was therefore not reviewed by people.